JBIO compared with DMRA: revenue, margins and what each company keeps, and the suppliers and customers both name

JBIOJade Biosciences, Inc.

Mkt capRevenueRevenue

DMRADamora Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

JBIOJade Biosciences, Inc.

DMRADamora Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

JBIO: latest quarter not drawable. DMRA: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only JBIO 3

—Patheon Biologicsunlistedsupplier

—WuXi Biologics (Hong Kong)unlistedsupplier

—WuXi Biologics Irelandunlistedsupplier

Shared 0

No shared counterparties.

Only DMRA 3

—Paragonunlistedsupplier

—Pre-Acquisition Damoraunlistedsupplier

—Bridge Medicinesunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

JBIOJade Biosciences, Inc.

14.07▲+0.07%· post 13.90

Mkt cap$894.2M

DMRADamora Therapeutics, Inc.

21.61▲+0.56%· post 21.61

ClosedNov 2 '26

Mkt cap$1.3B

Compare

ClosedNov 2 '26

JBIOJade Biosciences, Inc.

DMRADamora Therapeutics, Inc.

14.07▲+0.07%post 13.90

Price

21.61▲+0.56%post 21.61

$894.2M

Mkt cap

$1.3B

JBIO14.07▲+0.07%vsDMRA21.61▲+0.56%ClosedNov 2 '26

Price

rebased to 0%

JBIO, solidDMRA, dashed